CLRB - Cellectar Biosciences, Inc.

QQQ $ 452.07 $ 3.15 (0.7 %)

DIA $ 398.66 $ 3.08 (0.78 %)

SPY $ 528.86 $ 2.92 (0.56 %)

TLT $ 92.22 $ 0.39 (0.42 %)

GLD $ 221.04 $ 1.80 (0.82 %)

Previous Close

$ 3.18

Open

$ 3.27

Bid

$ 3.46 x 200

Ask

$ 3.48 x 100

Day's Range

$ 3.27 - $ 3.48

52 Week Range

$ 1.36 - $ 4.45

Volume

677,414

Average Volume

Market Cap

93.32M

Beta (5Y Monthly)

$ 1.57

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-14-2024	03-31-2024	10-Q
2	03-27-2024	12-31-2023	10-K
3	11-13-2023	09-30-2023	10-Q
4	08-14-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	03-09-2023	12-31-2022	10-K
7	11-03-2022	09-30-2022	10-Q
8	08-05-2022	06-30-2022	10-Q
9	05-10-2022	03-31-2022	10-Q
10	03-21-2022	12-31-2021	10-K
11	11-08-2021	09-30-2021	10-Q
12	08-09-2021	06-30-2021	10-Q
13	05-10-2021	03-31-2021	10-Q
14	03-02-2021	12-31-2020	10-K
15	11-09-2020	09-30-2020	10-Q
16	08-10-2020	06-30-2020	10-Q
17	05-07-2020	03-31-2020	10-Q
18	03-09-2020	12-31-2019	10-K
19	11-12-2019	09-30-2019	10-Q
20	08-12-2019	06-30-2019	10-Q
21	05-06-2019	03-31-2019	10-Q
22	02-26-2019	12-31-2018	10-K
23	11-13-2018	09-30-2018	10-Q
24	08-10-2018	06-30-2018	10-Q
25	05-11-2018	03-31-2018	10-Q
26	03-21-2018	12-31-2017	10-K
27	11-09-2017	09-30-2017	10-Q
28	08-14-2017	06-30-2017	10-Q
29	05-11-2017	03-31-2017	10-Q
30	03-15-2017	12-31-2016	10-K
31	11-10-2016	09-30-2016	10-Q
32	08-11-2016	06-30-2016	10-Q
33	05-12-2016	03-31-2016	10-Q
34	03-11-2016	12-31-2015	10-K
35	11-12-2015	09-30-2015	10-Q
36	08-12-2015	06-30-2015	10-Q
37	05-20-2015	03-31-2015	10-Q
38	03-24-2015	12-31-2014	10-K
39	11-12-2014	09-30-2014	10-Q
40	08-04-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Cellectar Biosciences' Cash and Cash Equiv...
05/14/2024 10:48:39

Cellectar Biosciences Q1 2024 GAAP EPS $(0...
05/14/2024 10:34:59

Roth MKM Maintains Buy on Cellectar Biosci...
03/28/2024 17:03:11

Roth MKM analyst Jonathan Aschoff maintains Cellectar Biosciences (NASDAQ:CLRB) with a Buy and raises the price target from ...

Oppenheimer Reiterates Outperform on Celle...
03/28/2024 11:33:33

Oppenheimer analyst Jeff Jones reiterates Cellectar Biosciences (NASDAQ:CLRB) with a Outperform and raises the price target ...

Cellectar Biosciences Says Cash and Cash ...
03/27/2024 10:52:03

Cellectar Biosciences Q4 EPS $(0.40) Beats...
03/27/2024 10:51:27

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of...

Earnings Scheduled For March 27, 2024
03/27/2024 09:02:44

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on rev...

Earnings Preview For Cellectar Biosciences
03/26/2024 17:00:44

cellectar-biosciences-is-an-attractive-acquisition-target-according-to-this-analyst---heres-why

Cellectar Biosciences Is An 'Attractive Ac...
03/04/2024 18:48:03

Cellectar Biosciences reports positive Phase 1 trial results for iopofosine I 131 in head and neck squamous cell carcinoma, ach...

Roth MKM Reiterates Buy on Cellectar Biosc...
03/04/2024 16:44:46

Roth MKM analyst Jonathan Aschoff reiterates Cellectar Biosciences (NASDAQ:CLRB) with a Buy and maintains $20 price target.

Cellectar Biosciences Announced That Iopof...
03/04/2024 11:42:06

Complete Remission rate of 64% and Overall Response Rate of 73% demonstrated in highly refractory patients Durability of ...

$cellectar-biosciences-has-enrolled-the-first-patient-in-its-phase-1b-clinical-trial-evaluating-iopofosine-i-131-in-pediatric-patients-with-relapsed-or-refractory-malignant-high-grade-gliomas$

Cellectar Biosciences Has Enrolled The Fir...
01/30/2024 11:45:35

Cellectar Biosciences Says Tranche A Warra...
01/25/2024 11:45:41

$cellectar-biosciences-iopofosine-i-131-demonstrated-complete-clonal-clearance-in-a-relapsedrefractory-waldenstroms-macroglobulinemia-patient-with-cns-involvement-enrolled-in-its-phase-2b-clover-wam-trial$

Cellectar Biosciences' Iopofosine I 131, D...
01/22/2024 11:42:41

Cellectar Biosciences Announced Preclinica...
01/16/2024 11:41:53

In preclinical studies, CLR 121225 demonstrated potent anti-tumor activity in refractory pancreatic cancer mouse xenograft mode...

Cellectar Biosciences Has Partnered To Adv...
01/11/2024 11:55:42

why-is-cancer-focused-cellectar-biosciences-stock-trading-higher-today

Why Is Cancer-Focused Cellectar Bioscience...
01/08/2024 16:15:32

Cellectar Biosciences Inc (NASDAQ: CLRB) announced data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a targe...

Cellectar Biosciences Announces Topline Da...
01/08/2024 11:32:19

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, developmen...

Cellectar Biosciences Expands A New Licens...
12/19/2023 13:33:53

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, developmen...

Cellectar Biosciences Strengthens Intellec...
12/12/2023 13:35:06

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, developmen...